GlobeNewsWire·Oct 5, 2026
Endovia and Lupvindol BioSciences Announce FDA Determination that CannEpil® for Canine Bone Cancer Pain Qualifies as a Minor Use, Establishing Eligibility for Conditional Approval PathwayFORT LAUDERDALE, Fla., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Endovia Health Sciences, Inc. (“Endovia” or the “Company”) (NYSE American: EDVA), in association with Lupvindol BioSciences (“Lupvindol”), today announced that the U.S. Food and Drug Administration's (“FDA”) Center for Veterinary Medicine has determined that the proposed use of CannEpil®, an investigational cannabidiol (“CBD”) and tetrahydrocannabinol (“THC”) oral solution, for the control of pain associated with bone cancer in dogs qualifies as a “minor use” under the Minor Use and Minor Species (“MUMS”) program.
